Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports

Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab (百泽安, Baize’an; BeiGene Ltd.) therapy...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: Jin Ho Baek
Format: Artigo
Langue:Inglês
Publié: Yeungnam University College of Medicine, Yeungnam University Institute Medical Science 2022-01-01
Collection:Journal of Yeungnam Medical Science
Sujets:
adverse events
immune checkpoint inhibitors
stomach neoplasms
tislelizumab
Accès en ligne:http://www.e-jyms.org/upload/pdf/yujm-2021-00934.pdf
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires